Lightlake Therapeutics has announced that the US National Institute on Drug Abuse (NIDA) wiill sponsor a Phase 1 pharmacokinetic study of Lightlake’s intranasal naloxone. If the results of the study are positive, the company said, NIDA will file an IND for further studies, with the goal of an FDA approval for intranasal naloxone for the reversal of opioid overdose within 18 months.
Lightlake CEO Roger Crystal commented, “Naloxone is a lifesaving drug used in an emergency to treat patients who have overdosed on opioids such as heroin or oxycodone. It’s proven to be very safe and has been used for decades. The problem is that it’s not readily available and only approved for administered through injection. We are working with NIDA to create an intranasal delivery system that can make naloxone much easier to use and more accessible for first responders, paramedics and families and friends of addicts who are at risk of overdose.”
The company is also developing intranasal naloxone for the treatment of binge eating disorder and for bulimia nervosa.
Read the Lightlake press release.
